Home Healthcare Biotechnology Peptide Antibiotics Market

Peptide Antibiotics Market Size, Share & Trends Analysis Report By Type (Ribosomal Synthesized Peptide Antibiotics, Non-ribosomal Synthesized Peptide Antibiotics), By Route of Administration (Parenteral, Oral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Peptide Antibiotics Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Ribosomal Synthesized Peptide Antibiotics
    2. Non-ribosomal Synthesized Peptide Antibiotics
  2. Peptide Antibiotics Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Parenteral
    2. Oral
    3. Topical
  3. Peptide Antibiotics Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Others
  4. Regional Peptide Antibiotics Market
    1. North America
      1. North America Peptide Antibiotics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
      2. North America Peptide Antibiotics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
        3. Topical
      3. North America Peptide Antibiotics Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Others
      4. U.S.
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      5. Canada
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
    2. Europe
      1. Europe Peptide Antibiotics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
      2. Europe Peptide Antibiotics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
        3. Topical
      3. Europe Peptide Antibiotics Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Others
      4. U.K.
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      5. Germany
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      6. France
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      7. Spain
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      8. Italy
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      9. Russia
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      10. Nordic
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      11. Benelux
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      12. Rest of Europe
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
    3. APAC
      1. APAC Peptide Antibiotics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
      2. APAC Peptide Antibiotics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
        3. Topical
      3. APAC Peptide Antibiotics Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Others
      4. China
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      5. Korea
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      6. Japan
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      7. India
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      8. Australia
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      9. Taiwan
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      10. South East Asia
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      11. Rest of Asia-Pacific
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
    4. Middle East and Africa
      1. Middle East and Africa Peptide Antibiotics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
      2. Middle East and Africa Peptide Antibiotics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
        3. Topical
      3. Middle East and Africa Peptide Antibiotics Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Others
      4. UAE
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      5. Turkey
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      6. Saudi Arabia
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      7. South Africa
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      8. Egypt
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      9. Nigeria
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      10. Rest of MEA
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
    5. LATAM
      1. LATAM Peptide Antibiotics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
      2. LATAM Peptide Antibiotics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
        3. Topical
      3. LATAM Peptide Antibiotics Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Others
      4. Brazil
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      5. Mexico
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      6. Argentina
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      7. Chile
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      8. Colombia
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
      9. Rest of LATAM
        1. Ribosomal Synthesized Peptide Antibiotics
        2. Non-ribosomal Synthesized Peptide Antibiotics
        3. Parenteral
        4. Oral
        5. Topical
        6. Hospital Pharmacies
        7. Retail Pharmacies
        8. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.